Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 2/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | CDA | P32320 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11131926 | 0.69 | SMN1; SMN2 (0.47) | ALDH1A1SLC18A3 | |
| SCHEMBL11131918 | 0.69 | SMN1; SMN2 (0.47) | ALDH1A1SLC18A3 | |
| SCHEMBL11131933 | 0.69 | SMN1; SMN2 (0.47) | ALDH1A1SLC18A3 | |
| SCHEMBL13403264 | 0.68 | SMN1; SMN2 (0.46) | ALDH1A1SLC18A3 | |
| SCHEMBL23227241 | 0.67 | PLA2G7 (0.33) | PLA2G7 | |
| SCHEMBL18577147 | 0.66 | SLC18A3 (0.39) | ALDH1A1SLC18A3 | |
| SCHEMBL2976800 | 0.66 | — | — | |
| SCHEMBL7078889 | 0.65 | SLC18A3 (0.41) | SLC18A3 | |
| SCHEMBL7078885 | 0.65 | SLC18A3 (0.41) | SLC18A3 | |
| SCHEMBL7078891 | 0.65 | SLC18A3 (0.41) | SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076438-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021127071-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |